Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serigne Lo

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
Cancer Cell|February 13, 2019
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyTuba N Gide, Camelia Quek, Alexander M Menzies, et al.
Pigment Cell & Melanoma Research|February 16, 2019
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesInes Pires da Silva, Isabella C Glitza, Lauren E Haydu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapyAmelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.
Nature Medicine|February 9, 2021
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapyRachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Journal of the National Cancer Institute|March 14, 2019
Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 CentersClio Dessinioti, Niki Dimou, Alan C Geller, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Nature Communications|July 20, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetsFelicity Newell, Yan Kong, James S Wilmott, et al.
Journal for Immunotherapy of Cancer|January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionAljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
Cancer Cell|February 13, 2019
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyTuba N Gide, Camelia Quek, Alexander M Menzies, et al.
Pigment Cell & Melanoma Research|February 16, 2019
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesInes Pires da Silva, Isabella C Glitza, Lauren E Haydu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapyAmelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.
Nature Medicine|February 9, 2021
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapyRachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Journal of the National Cancer Institute|March 14, 2019
Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 CentersClio Dessinioti, Niki Dimou, Alan C Geller, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Nature Communications|July 20, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetsFelicity Newell, Yan Kong, James S Wilmott, et al.
Journal for Immunotherapy of Cancer|January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionAljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Pageof 11